Investing Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease2024-04-01 Established Low Dose as Protected and Tolerable Dose in Present OCU410ST Scientific Trial DSMB Willpower to Proceed with Medium Dose…
